Prolonged Suppression of Neuropathic Pain by Sequential Delivery of Lidocaine and Thalidomide Drugs Using PEGylated Graphene Oxide

Journal of Pharmaceutical Sciences

Volumn 104, Issue 11, 2015, Pages 3851-3860

  Song, Tieying ^a   Gu, Kunfeng ^a   Wang, Wenli ^b   Wang, Hong ^a   Yang, Yunliang ^c   Yang, Lijun ^a   Ma, Pengxu ^a   Ma, Xiaojing ^a   Zhao, Jianhui ^a   Yan, Ruyu ^a   Guan, Jiao ^a   Wang, Chunping ^a   Qi, Yan ^a   Ya, Jian ^a  

^a FIRST HOSPITAL OF SHIJIAZHUANG   (China)

^b Physics Staff Room   (China)

^c HEBEI MEDICAL UNIVERSITY   (China)

Author keywords

biomaterials; cell biology; cell culture; CNS; controlled release delivery; drug interactions; drug transport; facilitated diffusion transport; in vitro models; nanotechnology

Indexed keywords

GRAPHENE OXIDE; INTERLEUKIN 1BETA; INTERLEUKIN 6; LIDOCAINE; MACROGOL; NANOSHEET; NITRIC OXIDE; THALIDOMIDE; TUMOR NECROSIS FACTOR ALPHA; CYTOKINE; DELAYED RELEASE FORMULATION; GRAPHITE; IMMUNOSUPPRESSIVE AGENT; LOCAL ANESTHETIC AGENT; OXIDE;

ANALGESIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOKINE RELEASE; DRUG BLOOD LEVEL; DRUG DELIVERY SYSTEM; IN VITRO STUDY; IN VIVO STUDY; MECHANICAL ALLODYNIA TEST; MOUSE; MTT ASSAY; NEUROPATHIC PAIN; NEWBORN; NONHUMAN; PAIN ASSESSMENT; PAIN THRESHOLD; SUSTAINED DRUG RELEASE; ANIMAL; ANTAGONISTS AND INHIBITORS; C57BL MOUSE; CELL CULTURE; CHEMISTRY; DELAYED RELEASE FORMULATION; HUMAN; HYPERALGESIA; IMMUNOLOGY; MALE; NEURALGIA;

ANESTHETICS, LOCAL; ANIMALS; CELLS, CULTURED; CYTOKINES; DELAYED-ACTION PREPARATIONS; GRAPHITE; HUMANS; HYPERALGESIA; IMMUNOSUPPRESSIVE AGENTS; LIDOCAINE; MALE; MICE; MICE, INBRED C57BL; NEURALGIA; OXIDES; THALIDOMIDE;

EID: 84944154485     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.24598     Document Type: Article

References (36)

1. Jensen TS, Finnerup NB,. 2014. Allodynia and hyperalgesia in neuropathic pain: Clinical manifestations and mechanisms. Lancet Neurol 13 (9): 924-935.
2. Baron R, Binder A, Wasner G,. 2010. Neuropathic pain: Diagnosis, pathophysiological mechanisms, and treatment. Lancet Neurol 9 (8): 807-819.
3. Abdi S, Lee DH, Chung JM,. 1998. The anti-allodynic effects of amitriptyline, gabapentin, and lidocaine in a rat model of neuropathic pain. Anesth Analg 87 (6): 1360-1366.
4. Mao J, Chen LL,. 2000. Systemic lidocaine for neuropathic pain relief. Pain 87 (1): 7-17.
5. George A, Marziniak M, Schafers M, Toyka KV, Sommer C,. 2000. Thalidomide treatment in chronic constrictive neuropathy decreases endoneurial tumor necrosis factor-alpha, increases interleukin-10 and has long-term effects on spinal cord dorsal horn met-enkephalin. Pain 88 (3): 267-275.
6. Teo SK, Colburn WA, Tracewell WG, Kook KA, Stirling DI, Jaworsky MS, Scheffler MA, Thomas SD, Laskin OL,. 2004. Clinical pharmacokinetics of thalidomide. Clin Pharmacokinet 43 (5): 311-327.
7. Huang S-T, Ho C-S, Lin C-M, Fang H-W, Peng Y-X,. 2008. Development and biological evaluation of C60 fulleropyrrolidine-thalidomide dyad as a new anti-inflammation agent. Bioorg Med Chem 16 (18): 8619-8626.
8. Krenn M, Gamcsik MP, Vogelsang GB, Colvin OM, Leong KW,. 1992. Improvements in solubility and stability of thalidomide upon complexation with hydroxypropyl-β-cyclodextrin. J Pharm Sci 81 (7): 685-689.
9. Chen H, Gu Y, Hu Y,. 2008. Comparison of two polymeric carrier formulations for controlled release of hydrophilic and hydrophobic drugs. J Mater Sci 19 (2): 651-658.
10. Araújo FA, Kelmann RG, Araújo BV, Finatto RB, Teixeira HF, Koester LS,. 2011. Development and characterization of parenteral nanoemulsions containing thalidomide. Eur J Pharm Sci 42 (3): 238-245.
11. Görner T, Gref R, Michenot D, Sommer F, Tran MN, Dellacherie E,. 1999. Lidocaine-loaded biodegradable nanospheres. I. Optimization of the drug incorporation into the polymer matrix. J Control Release 57 (3): 259-268.
12. Pjanovic R, Boškovic-Vragolovic N, Veljkovic-Giga J, Garic-Grulovic R, Pejanovic S, Bugarski B,. 2010. Diffusion of drugs from hydrogels and liposomes as drug carriers. J Chem Technol Biotechnol 85 (5): 693-698.
13. Wen H, Dong C, Dong H, Shen A, Xia W, Cai X, Song Y, Li X, Li Y, Shi D,. 2012. Engineered redox-responsive PEG detachment mechanism in PEGylated nano-graphene oxide for intracellular drug delivery. Small 8 (5): 760-769.
14. Liu Z, Robinson JT, Sun X, Dai H,. 2008. PEGylated nanographene oxide for delivery of water-insoluble cancer drugs. J Am Chem Soc 130 (33): 10876-10877.
15. Sun X, Liu Z, Welsher K, Robinson JT, Goodwin A, Zaric S, Dai H,. 2008. Nano-graphene oxide for cellular imaging and drug delivery. Nano Res 1 (3): 203-212.
16. Zhang S, Xiong P, Yang X, Wang X,. 2011. Novel PEG functionalized graphene nanosheets: Enhancement of dispersibility and thermal stability. Nanoscale 3 (5): 2169-2174.
17. Zhang X, Huang PJ, Servos MR, Liu J,. 2012. Effects of polyethylene glycol on DNA adsorption and hybridization on gold nanoparticles and graphene oxide. Langmuir 28 (40): 14330-14337.
18. Li B, Zhang XY, Yang JZ, Zhang YJ, Li WX, Fan CH, Huang Q,. 2014. Influence of polyethylene glycol coating on biodistribution and toxicity of nanoscale graphene oxide in mice after intravenous injection. Int J Nanomedicine 9: 4697-4707.
19. Stankovich S, Dikin DA, Piner RD, Kohlhaas KA, Kleinhammes A, Jia Y, Wu Y, Nguyen ST, Ruoff RS,. 2007. Synthesis of graphene-based nanosheets via chemical reduction of exfoliated graphite oxide. Carbon 45 (7): 1558-1565.
20. Hummers WS Jr, Offeman RE,. 1958. Preparation of graphitic oxide. J Am Chem Soc 80 (6): 1339-1339.
21. Zhang L, Xia J, Zhao Q, Liu L, Zhang Z,. 2010. Functional graphene oxide as a nanocarrier for controlled loading and targeted delivery of mixed anticancer drugs. Small 6 (4): 537-544.
22. Yang X, Zhang X, Liu Z, Ma Y, Huang Y, Chen Y,. 2008. High-efficiency loading and controlled release of doxorubicin hydrochloride on graphene oxide. J Phys Chem C 112 (45): 17554-17558.
23. Suzuki N, Hasegawa-Moriyama M, Takahashi Y, Kamikubo Y, Sakurai T, Inada E,. 2011. Lidocaine attenuates the development of diabetic-induced tactile allodynia by inhibiting microglial activation. Anesthesia & Analgesia 113 (4): 941-946.
24. Zimmermann M,. 1983. Ethical guidelines for investigations of experimental pain in conscious animals. Pain 16: 109-110.
25. Sharma S, Kulkarni SK, Agrewala JN, Chopra K,. 2006. Curcumin attenuates thermal hyperalgesia in a diabetic mouse model of neuropathic pain. Eur J Pharmacol 536 (3): 256-261.
26. Qi X, Pu K-Y, Li H, Zhou X, Wu S, Fan Q-L, Liu B, Boey F, Huang W, Zhang H,. 2010. Amphiphilic graphene composites. Angew Chem Int Ed 49 (49): 9426-9429.
27. Stankovich S, Piner RD, Nguyen ST, Ruoff RS,. 2006. Synthesis and exfoliation of isocyanate-treated graphene oxide nanoplatelets. Carbon 44 (15): 3342-3347.
28. Chng EL, Pumera M,. 2013. The toxicity of graphene oxides: Dependence on the oxidative methods used. Chemistry 19 (25): 8227-8235.
29. Jastrzebska AM, Kurtycz P, Olszyna AR,. 2012. Recent advances in graphene family materials toxicity investigations. J Nanopart Res 14 (12): 1320.
30. Stemkowski PL, Smith PA,. 2012. Sensory neurons, ion channels, inflammation and the onset of neuropathic pain. Can J Neurol Sci 39 (4): 416-435.
31. Daemen MA, Kurvers HA, Kitslaar PJ, Slaaf DW, Bullens PH, Van den Wildenberg FA,. 1998. Neurogenic inflammation in an animal model of neuropathic pain. Neurol Res 20 (1): 41-45.
32. Lu CH, Yang HH, Zhu CL, Chen X, Chen GN,. 2009. A graphene platform for sensing biomolecules. Angew Chem Int Ed Engl 48 (26): 4785-4787.
33. Yang X, Dou X, Rouhanipour A, Zhi L, Rader HJ, Mullen K,. 2008. Two-dimensional graphene nanoribbons. J Am Chem Soc 130 (13): 4216-4217.
34. Nakanishi M, Hata K, Nagayama T, Sakurai T, Nishisho T, Wakabayashi H, Hiraga T, Ebisu S, Yoneda T,. 2010. Acid activation of Trpv1 leads to an up-regulation of calcitonin gene-related peptide expression in dorsal root ganglion neurons via the CaMK-CREB cascade: A potential mechanism of inflammatory pain. Mol Biol Cell 21 (15): 2568-2577.
35. White JP, Cibelli M, Rei Fidalgo A, Paule CC, Noormohamed F, Urban L, Maze M, Nagy I,. 2010. Role of transient receptor potential and acid-sensing ion channels in peripheral inflammatory pain. Anesthesiology 112 (3): 729-741.
36. Milligan ED, Watkins LR,. 2009. Pathological and protective roles of glia in chronic pain. Nat Rev Neurosci 10 (1): 23-36.